BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Inc. as CMO. Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc....
BioCentury | Jul 17, 2020
Finance

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

...people are concerned about,” da Silva said during the webinar. Scott Koenig , CEO of MacroGenics Inc....
...that said the question did not apply to them (see “API Supply”). Figure: API supply MacroGenics...
...between revenue-generating and pre-revenue companies (see “Survey Demographics”). Figure: Survey demographics Amanda Micklus, Senior Biopharma Analyst Immunocore Ltd. MacroGenics Inc. BeiGene...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...They include FGFR2b program bemarituzumab from Five Prime Therapeutics Inc. (NASDAQ:FPRX); HER2-targeting mAb margetuximab from MacroGenics Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...June 29. Spellman was CFO and CBO at Intarcia Therapeutics Inc. Antibody cancer therapeutics company MacroGenics Inc....
...Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...financing, Cullinan announced the appointment of Jon Wigginton as CMO. He was previously CMO at MacroGenics Inc....
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...led to two PSA responses among eight evaluable patients with metastatic castration-resistant prostate cancer (mCRPC). MacroGenics...
...antibody data Investors also weren’t very impressed with updated Phase I data for MGD013 from MacroGenics Inc....
...combination therapy with anti-HER2 mAb margetuximab showed a 50% response rate in six evaluable patients. MacroGenics...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...HER2 and HER3 ( No. TS3654 ), the PD-1 x LAG3 bispecific antibody MDG013 from MacroGenics Inc....
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...from a different LAG3 will be presented at ASCO. The bispecific, tetravalent antibody MGC018 from MacroGenics Inc....
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

...to show benefit over the PD-1 inhibitor alone (see “Lessons from the ECHO Chamber” ). MacroGenics’...
...example of a novel checkpoint inhibitor that’s showing early efficacy signals at ASCO came from MacroGenics Inc....
BioCentury | May 7, 2020
Product Development

ASCO preview carries MacroGenics to $1B valuation

...on the company’s 1Q20 earnings call Tuesday and provided updates on two other clinical programs. MacroGenics Inc....
...29 through June 2, feature new Phase I data on MGD013 and MGD018. Koenig said MacroGenics...
...Margetuximab is under FDA review to treat HER2-positive, metastatic breast cancer in combination with chemotherapy. MacroGenics...
Items per page:
1 - 10 of 235
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Inc. as CMO. Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc....
BioCentury | Jul 17, 2020
Finance

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

...people are concerned about,” da Silva said during the webinar. Scott Koenig , CEO of MacroGenics Inc....
...that said the question did not apply to them (see “API Supply”). Figure: API supply MacroGenics...
...between revenue-generating and pre-revenue companies (see “Survey Demographics”). Figure: Survey demographics Amanda Micklus, Senior Biopharma Analyst Immunocore Ltd. MacroGenics Inc. BeiGene...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...They include FGFR2b program bemarituzumab from Five Prime Therapeutics Inc. (NASDAQ:FPRX); HER2-targeting mAb margetuximab from MacroGenics Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...June 29. Spellman was CFO and CBO at Intarcia Therapeutics Inc. Antibody cancer therapeutics company MacroGenics Inc....
...Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...financing, Cullinan announced the appointment of Jon Wigginton as CMO. He was previously CMO at MacroGenics Inc....
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...led to two PSA responses among eight evaluable patients with metastatic castration-resistant prostate cancer (mCRPC). MacroGenics...
...antibody data Investors also weren’t very impressed with updated Phase I data for MGD013 from MacroGenics Inc....
...combination therapy with anti-HER2 mAb margetuximab showed a 50% response rate in six evaluable patients. MacroGenics...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...HER2 and HER3 ( No. TS3654 ), the PD-1 x LAG3 bispecific antibody MDG013 from MacroGenics Inc....
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...from a different LAG3 will be presented at ASCO. The bispecific, tetravalent antibody MGC018 from MacroGenics Inc....
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

...to show benefit over the PD-1 inhibitor alone (see “Lessons from the ECHO Chamber” ). MacroGenics’...
...example of a novel checkpoint inhibitor that’s showing early efficacy signals at ASCO came from MacroGenics Inc....
BioCentury | May 7, 2020
Product Development

ASCO preview carries MacroGenics to $1B valuation

...on the company’s 1Q20 earnings call Tuesday and provided updates on two other clinical programs. MacroGenics Inc....
...29 through June 2, feature new Phase I data on MGD013 and MGD018. Koenig said MacroGenics...
...Margetuximab is under FDA review to treat HER2-positive, metastatic breast cancer in combination with chemotherapy. MacroGenics...
Items per page:
1 - 10 of 235